We provide you with 20 years of free, institutional-grade data for FSTX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of FSTX. Explore the full financial landscape of FSTX stock.
| Reported Date | CIK | Ticker | Type |
|---|
F-star Therapeutics, Inc.(NASDAQ:FSTX) 
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in...
Website: https://www.f-star.com
Founded: 2002
Full Time Employees: 84
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about FSTX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.